[<sup>111</sup>In]In/[<sup>177</sup>Lu]Lu-AAZTA<sup>5</sup>-LM4 SST<sub>2</sub>R-Antagonists in Cancer Theranostics: From Preclinical Testing to First Patient Results

[<sup>111</sup>In]In/[<sup>177</sup>Lu]Lu-AAZTA<sup>5</sup>-LM4 SST<sub>2</sub>R-Antagonists in Cancer Theranostics: From Preclinical Testing to First Patient Results

Aiming to expand the application of the SST<sub>2</sub>R-antagonist LM4 (DPhe-c[DCys-4Pal-DAph(Cbm)-Lys-Thr-Cys]-DTyr-NH<sub>2</sub>) beyond [<sup>68</sup>Ga]Ga-DATA<sup>5m</sup>-LM4 PET/CT (DATA<sup>5m</sup>, (6-pentanoic acid)-6-(amino)me...

Full description

Bibliographic Details
Main Authors: Berthold A. Nock, Panagiotis Kanellopoulos, Euy Sung Moon, Maritina Rouchota, George Loudos, Sanjana Ballal, Madhav P. Yadav, Chandrasekhar Bal, Prashant Mishra, Parvind Sheokand, Frank Roesch, Theodosia Maina
Format: Article
Language:English
Published: MDPI AG 2023-02-01
Series:Pharmaceutics
Subjects:
somatostatin subtype 2 receptor (SST<sub>2</sub>R)-antagonist
AAZTA<sup>5</sup> chelator
AAZTA<sup>5</sup>-LM4
theranostics
neuroendocrine tumors
In-111
Online Access:https://www.mdpi.com/1999-4923/15/3/776

Internet

https://www.mdpi.com/1999-4923/15/3/776

Similar Items